{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T13:18:58Z","timestamp":1769087938349,"version":"3.49.0"},"reference-count":25,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Revista Espa\u00f1ola de Medicina Nuclear e Imagen Molecular (English Edition)"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.remnie.2025.500218","type":"journal-article","created":{"date-parts":[[2025,9,5]],"date-time":"2025-09-05T15:33:30Z","timestamp":1757086410000},"page":"500218","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Treatment with radionuclide-labeled peptides in refractory meningiomas: Updated review and clinical perspectives"],"prefix":"10.1016","volume":"45","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0193-828X","authenticated-orcid":false,"given":"E.","family":"Abou Jokh Casas","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.L.","family":"Vercher Conejero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Repetto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Bello Arques","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Cambil Molina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Rodriguez Gas\u00e9n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.A.","family":"Vallejo Casas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.remnie.2025.500218_bib0005","doi-asserted-by":"crossref","first-page":"3662","DOI":"10.1007\/s00259-024-06783-x","article-title":"Joint EANM\/EANO\/RANO\/SNMMI practice guideline\/procedure standards for diagnostics and therapy (theranostics) of meningiomas using radiolabeled somatostatin receptor ligands: version 1.0","volume":"51","author":"Albert","year":"2024","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.remnie.2025.500218_bib0010","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.3390\/pharmaceutics15041110","article-title":"Lutathera\u00ae orphans: state of the art and future application of radioligand therapy with 177Lu-DOTATATE","volume":"15","author":"Urso","year":"2023","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.remnie.2025.500218_bib0015","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1007\/s00401-016-1545-1","article-title":"The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary","volume":"131","author":"Louis","year":"2016","journal-title":"Acta Neuropathol"},{"key":"10.1016\/j.remnie.2025.500218_bib0020","first-page":"1911","article-title":"Intraarterial administration of peptide receptor radionuclide therapy in patients with advanced meningioma: initial safety and efficacy","volume":"65","author":"Amerein","year":"2024","journal-title":"J Nucl Med"},{"key":"10.1016\/j.remnie.2025.500218_bib0025","doi-asserted-by":"crossref","DOI":"10.2217\/cns-2021-0003","article-title":"Meningioma: not always a benign tumor. A review of advances in the treatment of meningiomas","volume":"10","author":"Maggio","year":"2021","journal-title":"CNS Oncol"},{"key":"10.1016\/j.remnie.2025.500218_bib0030","doi-asserted-by":"crossref","first-page":"217","DOI":"10.23736\/S1824-4785.24.03571-4","article-title":"177Lu-labeled somatostatin receptor targeted radionuclide therapy dosimetry in meningioma: a systematic review","volume":"68","author":"Boursier","year":"2024","journal-title":"Q J Nucl Med Mol Imaging"},{"issue":"Suppl 9","key":"10.1016\/j.remnie.2025.500218_bib0035","doi-asserted-by":"crossref","first-page":"S215","DOI":"10.1093\/neuonc\/noae069","article-title":"Radioligand therapies in meningioma: evidence and future directions","volume":"26","author":"Mair","year":"2024","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.remnie.2025.500218_bib0040","doi-asserted-by":"crossref","first-page":"347","DOI":"10.2967\/jnumed.114.149120","article-title":"Increased 68Ga-DOTATATE uptake in PET imaging discriminates meningioma and tumor-free tissue","volume":"56","author":"Rachinger","year":"2015","journal-title":"J Nucl Med"},{"key":"10.1016\/j.remnie.2025.500218_bib0045","doi-asserted-by":"crossref","first-page":"16","DOI":"10.3109\/01676830.2014.959185","article-title":"Ga-68-DOTA-TATE PET\/CT for discrimination of tumors of the optic pathway","volume":"34","author":"Klingenstein","year":"2015","journal-title":"Orbit"},{"key":"10.1016\/j.remnie.2025.500218_bib0050","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1186\/s13014-021-01875-6","article-title":"68Ga-DOTATATE PET-CT as a tool for radiation planning and evaluating treatment responses in the clinical management of meningiomas","volume":"16","author":"Kowalski","year":"2021","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.remnie.2025.500218_bib0055","doi-asserted-by":"crossref","first-page":"e29","DOI":"10.1016\/S1470-2045(23)00525-9","article-title":"PET-based response assessment criteria for diffuse gliomas (PET RANO 1.0): a report of the RANO group","volume":"25","author":"Albert","year":"2024","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.remnie.2025.500218_bib0060","doi-asserted-by":"crossref","first-page":"47","DOI":"10.2967\/jnumed.114.149120","article-title":"Increased 68Ga-DOTATATE uptake in PET imaging discriminates meningioma and tumor-free tissue","volume":"56","author":"Rachinger","year":"2015","journal-title":"J Nucl Med"},{"key":"10.1016\/j.remnie.2025.500218_bib0065","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1152\/ajpendo.00004.2005","article-title":"Distinct functional properties of native somatostatin receptor subtype 5 compared with subtype 2 in the regulation of ACTH release by corticotroph tumor cells","volume":"289","author":"Van-der-Hoek","year":"2005","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"10.1016\/j.remnie.2025.500218_bib0070","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1056\/NEJMoa1607427","article-title":"Phase 3 trial of 177Lu-dotatate for midgut neuroendocrine tumors","volume":"376","author":"Strosberg","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.remnie.2025.500218_bib0075","doi-asserted-by":"crossref","first-page":"406","DOI":"10.2967\/jnumed.121.262491","article-title":"Intraarterial administration boosts 177Lu-HA-DOTATATE accumulation in salvage meningioma patients","volume":"63","author":"Vonken","year":"2022","journal-title":"J Nucl Med"},{"key":"10.1016\/j.remnie.2025.500218_bib0080","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1007\/s00270-019-02262-1","article-title":"Will 177Lu-DOTATATE treatment become more effective in salvage meningioma patients, when boosting somatostatin receptor saturation? A promising case on intra-arterial administration","volume":"42","author":"Braat","year":"2019","journal-title":"Cardiovasc Intervent Radiol"},{"key":"10.1016\/j.remnie.2025.500218_bib0085","first-page":"22","article-title":"Long-term results of multimodal peptide receptor radionuclide therapy and fractionated external beam radiotherapy for treatment of advanced symptomatic meningioma","volume":"22","author":"Hartrampf","year":"2020","journal-title":"Clin Transl Radiat Oncol"},{"key":"10.1016\/j.remnie.2025.500218_bib0090","doi-asserted-by":"crossref","first-page":"2364","DOI":"10.3390\/jcm11092364","article-title":"The current role of peptide receptor radionuclide therapy in meningiomas","volume":"11","author":"Fodi","year":"2022","journal-title":"J Clin Med"},{"key":"10.1016\/j.remnie.2025.500218_bib0095","doi-asserted-by":"crossref","first-page":"5550","DOI":"10.3390\/curroncol29080438","article-title":"Somatostatin receptor theranostics for refractory meningiomas","volume":"29","author":"Salgues","year":"2022","journal-title":"Curr Oncol"},{"key":"10.1016\/j.remnie.2025.500218_bib0100","doi-asserted-by":"crossref","first-page":"507","DOI":"10.2967\/jnumed.120.249607","article-title":"Somatostatin receptor-targeted radiopeptide therapy in treatment-refractory meningioma: individual patient data meta-analysis","volume":"62","author":"Mirian","year":"2021","journal-title":"J Nucl Med"},{"key":"10.1016\/j.remnie.2025.500218_bib0105","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1158\/1078-0432.CCR-23-2533","article-title":"Evaluation of the SSTR2-targeted Radiopharmaceutical 177Lu-DOTATATE and SSTR2-specific 68Ga-DOTATATE PET as Imaging Biomarker in Patients with Intracranial Meningioma","volume":"30","author":"Kurz","year":"2024","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.remnie.2025.500218_bib0110","first-page":"1538","article-title":"Somatostatin receptor-targeted radionuclide therapy for progressive meningioma: benefit linked to 68Ga-DOTATATE\/-TOC uptake","volume":"18","author":"Seystahl","year":"2016","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.remnie.2025.500218_bib0115","doi-asserted-by":"crossref","first-page":"171","DOI":"10.2967\/jnumed.114.147256","article-title":"Somatostatin receptor-targeted radiopeptide therapy with 90Y-DOTATOC and 177Lu-DOTATOC in progressive meningioma: long-term results of a phase II clinical trial","volume":"56","author":"Marincek","year":"2015","journal-title":"J Nucl Med"},{"key":"10.1016\/j.remnie.2025.500218_bib0120","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1007\/s00259-022-06044-9","article-title":"Efficacy and safety of peptide receptor radionuclide therapy with [177Lu]Lu-DOTA-TATE in 15 patients with progressive treatment-refractory meningioma","volume":"50","author":"Minczeles","year":"2023","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.remnie.2025.500218_bib0125","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1007\/s00259-023-06226-z","article-title":"EANM enabling guide: how to improve the accessibility of clinical dosimetry","volume":"50","author":"Gear","year":"2023","journal-title":"Eur J Nucl Med Mol Imaging"}],"container-title":["Revista Espa\u00f1ola de Medicina Nuclear e Imagen Molecular (English Edition)"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2253808925001259?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2253808925001259?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T21:22:00Z","timestamp":1769030520000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2253808925001259"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":25,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["S2253808925001259"],"URL":"https:\/\/doi.org\/10.1016\/j.remnie.2025.500218","relation":{},"ISSN":["2253-8089"],"issn-type":[{"value":"2253-8089","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment with radionuclide-labeled peptides in refractory meningiomas: Updated review and clinical perspectives","name":"articletitle","label":"Article Title"},{"value":"Revista Espa\u00f1ola de Medicina Nuclear e Imagen Molecular (English Edition)","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.remnie.2025.500218","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.remn.2025.500218","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Sociedad Espa\u00f1ola de Medicina Nuclear e Imagen Molecular. Published by Elsevier Espa\u00f1a, S.L.U. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"500218"}}